Stock Events

Stock Events

Panbela Therapeutics 

$0
32
-$0-96% Wednesday 20:00

Statistics

Day High
0.02
Day Low
0.02
52W High
2.5
52W Low
0
Volume
1,012
Avg. Volume
508
Mkt Cap
971
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

20MayExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-65.9
-44.42
-22.95
-1.47
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-50.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBLA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes in the development of treatments for cancer, a key focus area for Panbela Therapeutics.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on human therapeutics, including cancer treatments which puts it in direct competition with Panbela Therapeutics in the oncology sector.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is known for its strong portfolio in oncology, directly competing with Panbela Therapeutics in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer drugs among other areas, making it a competitor to Panbela Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a broad range of drugs, including cancer treatments that compete with Panbela Therapeutics' offerings.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, with its extensive research and development in oncology, competes with Panbela Therapeutics in the cancer drug market.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a major player in the pharmaceutical and diagnostics world, with a significant focus on oncology, competing with Panbela Therapeutics.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong presence in the oncology sector, developing treatments that compete with Panbela Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including cancer, making it a competitor.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments, competing with Panbela Therapeutics.

About

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Show more...
CEO
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
Employees
7
Country
US
ISIN
US69833W4042

Listings

OTC Link
US
PBLA

0 Comments

Share your thoughts

FAQ

What is Panbela Therapeutics stock price today?▼
The current price of PBLA is $0 USD — it has decreased by -96% in the past 24 hours. Watch Panbela Therapeutics stock price performance more closely on the chart.
What is Panbela Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Panbela Therapeutics stocks are traded under the ticker PBLA.
Is Panbela Therapeutics stock price growing?▼
PBLA stock has risen by +0% compared to the previous week, the month change is a -98.18% fall, over the last year Panbela Therapeutics has showed a -99.94% decrease.
What is Panbela Therapeutics market cap?▼
Today Panbela Therapeutics has the market capitalization of 971
What is Panbela Therapeutics revenue for the last year?▼
Panbela Therapeutics revenue for the last year amounts to 0 USD.
What is Panbela Therapeutics net income for the last year?▼
PBLA net income for the last year is -50.53M USD.
How many employees does Panbela Therapeutics have?▼
As of April 04, 2026, the company has 7 employees.
In which sector is Panbela Therapeutics located?▼
Panbela Therapeutics operates in the Health Care sector.
When did Panbela Therapeutics complete a stock split?▼
The last stock split for Panbela Therapeutics was on January 18, 2024 with a ratio of 1:20.
Where is Panbela Therapeutics headquartered?▼
Panbela Therapeutics is headquartered in Waconia, US.